Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses - PubMed

Affiliations

• PMID: 19146897
• DOI: 10.1016/j.vaccine.2008.12.041

Comparative Study

Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses

Sohel Shamsuzzaman et al. Vaccine. 2009.

Abstract

The emergence of V. cholerae O139 serogroup of V. cholerae capable of causing severe dehydrating cholera has over the decade led to efforts in formulation of vaccines to protect against this pathogen. Although the prevalence of diarrhea due to V. cholerae O139 has recorded a decrease, efforts on vaccine development continues to formulate an oral vaccine capable of stimulating the gut mucosal system. We have studied the mucosal immunogenicity in Bangladeshi adults to a killed whole cell (WC) bivalent cholera vaccine composed of V. cholerae O139 as well as V. cholerae O1 strains together with the recombinant cholera toxin B subunit (CTB) (WC-O1/O139/CTB) and compared the immune responses to that obtained with the licensed monovalent cholera vaccine, Dukoral (WC-O1/CTB). Direct estimation of the WC-O1/O139/CTB vaccine-specific mucosal responses were carried out using lymphocytes isolated from duodenal biopsies, intestinal lavage fluid and feces. The vaccine induced robust antibody-secreting cell responses in the duodenum specific to CTB as well as the O1 and O139 lipopolysaccharide (LPS). Magnitude of response was higher in the gut than in the circulation in all three antibody isotypes. The CTB and LPS-specific mucosal antibody responses were also seen in intestinal lavage fluid and fecal extracts. Vibriocidal antibody responses in plasma were observed to both the V. cholerae O1 and O139 serogroups (76% and 57% response rates, respectively). Plasma IgA and IgG responses to CTB and IgA responses to both O1 and O139 LPS were elevated. The immune responses were comparable to that seen to the monovalent WC-O1/CTB recipients in all components studied. Overall, the bivalent cholera vaccine induces strong mucosal responses and the addition of the O139 component does not interfere with the responses to the licensed vaccine Dukoral. This sets the ground for testing such vaccines in large field trials in Bangladesh and also demonstrates that addition of other vibrio components to the existing cholera vaccine does not alter the responses to the O1 vaccine components.

Similar articles

• Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.

  Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F. Saha A, et al. Vaccine. 2011 Oct 26;29(46):8285-92. doi: 10.1016/j.vaccine.2011.08.108. Epub 2011 Sep 9. Vaccine. 2011. PMID: 21907255 Clinical Trial.

• Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.

  Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, Hung NV, Canh DG, Thiem VD, Naficy A, Ivanoff B, Svennerholm AM, Holmgren J, Clemens JD. Trach DD, et al. Bull World Health Organ. 2002;80(1):2-8. Bull World Health Organ. 2002. PMID: 11884967 Free PMC article. Clinical Trial.

• Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.

  Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA. Concha A, et al. Bull Pan Am Health Organ. 1995 Dec;29(4):312-21. Bull Pan Am Health Organ. 1995. PMID: 8605522 Clinical Trial.

• A review of the current status of enteric vaccines.

  Levine MM, Noriega F. Levine MM, et al. P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.

• Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.

  Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Holmgren J, et al. Am J Trop Med Hyg. 1994;50(5 Suppl):42-54. Am J Trop Med Hyg. 1994. PMID: 8203723 Review.

Cited by

• Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera.

  Alam MM, Riyadh MA, Fatema K, Rahman MA, Akhtar N, Ahmed T, Chowdhury MI, Chowdhury F, Calderwood SB, Harris JB, Ryan ET, Qadri F. Alam MM, et al. Clin Vaccine Immunol. 2011 May;18(5):844-50. doi: 10.1128/CVI.00562-10. Epub 2011 Feb 23. Clin Vaccine Immunol. 2011. PMID: 21346055 Free PMC article.

• Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.

  Akhtar M, Chowdhury MI, Bhuiyan TR, Kaim J, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Begum YA, Sharif MZ, Islam LN, Carlin N, Maier N, Fix A, Wierzba TF, Walker RI, Bourgeois AL, Svennerholm AM, Qadri F, Lundgren A. Akhtar M, et al. Vaccine. 2019 Sep 3;37(37):5645-5656. doi: 10.1016/j.vaccine.2018.11.040. Epub 2018 Nov 22. Vaccine. 2019. PMID: 30473185 Free PMC article. Clinical Trial.

• Activated T follicular helper-like cells are released into blood after oral vaccination and correlate with vaccine specific mucosal B-cell memory.

  Cárdeno A, Magnusson MK, Quiding-Järbrink M, Lundgren A. Cárdeno A, et al. Sci Rep. 2018 Feb 9;8(1):2729. doi: 10.1038/s41598-018-20740-3. Sci Rep. 2018. PMID: 29426881 Free PMC article.

• Vibrio cholerae, classification, pathogenesis, immune response, and trends in vaccine development.

  Montero DA, Vidal RM, Velasco J, George S, Lucero Y, Gómez LA, Carreño LJ, García-Betancourt R, O'Ryan M. Montero DA, et al. Front Med (Lausanne). 2023 May 5;10:1155751. doi: 10.3389/fmed.2023.1155751. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37215733 Free PMC article. Review.

• Impact of Immunoglobulin Isotype and Epitope on the Functional Properties of Vibrio cholerae O-Specific Polysaccharide-Specific Monoclonal Antibodies.

  Kauffman RC, Adekunle O, Yu H, Cho A, Nyhoff LE, Kelly M, Harris JB, Bhuiyan TR, Qadri F, Calderwood SB, Charles RC, Ryan ET, Kong J, Wrammert J. Kauffman RC, et al. mBio. 2021 Apr 20;12(2):e03679-20. doi: 10.1128/mBio.03679-20. mBio. 2021. PMID: 33879588 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal